Evidence map›Paper›PMID 38891032›Full record

ArticleCells2024

Using Microfluidic Hepatic Spheroid Cultures to Assess Liver Toxicity of T-2 Mycotoxin.

Mercedes Taroncher, Alan M Gonzalez-Suarez, Kihak Gwon, Samuel Romero, Angel D Reyes-Figueroa, Yelko Rodríguez-Carrasco, María-José Ruiz, Gulnaz Stybayeva, Alexander Revzin, Jose M de Hoyos-Vega

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Development and Validation of a Scaffold-Free Human Multilineage Spheroid Model for Early Stage Cholangiopathies Driven by Cholangiocyte Senescence.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mercedes TaroncherDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55901, USA.ORCID 0000-0002-8752-0951
Alan M Gonzalez-SuarezDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55901, USA.ORCID 0000-0001-6442-4353
Kihak GwonDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55901, USA.
Samuel RomeroCentro de Investigación en Matemáticas Unidad Monterrey, Apodaca 66628, NL, Mexico.
Angel D Reyes-FigueroaCentro de Investigación en Matemáticas Unidad Monterrey, Apodaca 66628, NL, Mexico.ORCID 0000-0001-6436-6755
Yelko Rodríguez-CarrascoResearch Group in Alternative Methods for Determining Toxics Effects and Risk Assessment of Contaminants and Mixtures (RiskTox), Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain.ORCID 0000-0002-6421-218X
María-José RuizResearch Group in Alternative Methods for Determining Toxics Effects and Risk Assessment of Contaminants and Mixtures (RiskTox), Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain.ORCID 0000-0003-4174-6688
Gulnaz StybayevaDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55901, USA.ORCID 0000-0002-1453-245X
Alexander RevzinDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55901, USA.
Jose M de Hoyos-VegaDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55901, USA.ORCID 0000-0001-7537-1090

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Samar Ibrahim · 2009 to 2026
$22.2M
Mass spectrometry for highly sensitive and sample-sparing analysis of extracellular vesicles in liver diseasesR01DK134661 · NIDDK · MAYO CLINIC ROCHESTER · PI Alexander Revzin, EMILE Alfred SCHWEIKERT · 2023 to 2026
$2.6M
A microfluidic cell culture platform for personalizing pancreatic cancer therapiesR21CA236612 · NCI · MAYO CLINIC ROCHESTER · PI REVZIN, ALEXANDER · 2020 to 2021
$582k
NCI NIH HHS R21 CA236612NIDDK NIH HHS P30 DK084567NIH HHS 1R01DK134661-24A1
6 · The paper itself

Abstract

The

Indexed as

LiverSpheroids, CellularT-2 ToxinCell SurvivalCoculture TechniquesHepatocytesHep G2 CellsHumansMicrofluidicsT-2 ToxincytotoxicityHepG2 cellsmicrofluidic devicesspheroidsT-2

Identifiers

PMID38891032
PMCPMC11172061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.